FTC Would Shred Privilege In Aggrenox Suit, DC Circ. Told
The Federal Trade Commission's bid to force Boehringer Ingelheim to hand over documents relating to a 2008 patent dispute settlement with Barr Pharmaceuticals over the drug Aggrenox would eviscerate the attorney-client...To view the full article, register now.
Already a subscriber? Click here to view full article